AstraZeneca's Evusheld and GSK's sotrovimab lose efficacy against Omicron's subvariants
Two key Covid-19 drugs don’t perform as well against Omicron’s subvariants as they did against the original version, and in the case of AstraZeneca’s pre …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
